SCV-07: Completed Phase II enrollment

SciClone completed enrollment of 60 patients receiving chemotherapy for head and neck cancer in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 0.02 or 0.10 mg/kg SCV-07 for about 7...